Compare Enveric Biosciences Inc (ENVB) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs H2O America — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while H2O America trades at $62.03 (market cap $2.61B). The key difference: H2O America is far larger — about 421× Enveric Biosciences Inc's market cap, and H2O America pays a 2.83% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | HTO | |
|---|---|---|
Market Cap | $6.20M | $2.61B |
Sector | Health | Technology |
52-Week High | $17.40 | $65.43 |
52-Week Low | $1.27 | $44.44 |
Enterprise Value | $1.30M | $4.40B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
HTO trades at $62.66, up 1.42% with a bullish technical signal supported by moving averages. The company reported mixed earnings with Q2 2026 EPS beating expectations at $0.72 versus $0.699, but Q4 2025 missed. Fundamentals show strong gross margins at 56.91% and revenue growth to $829M projected for 2026. Recent news highlights institutional acquisitions and transformative Texas water utility expansion via the Quadvest deal.
Outlook remains positive with analyst consensus Buy rating (83%) and $69.50 price target offering ~11% upside. Key risks include execution challenges from acquisitions and EPS dilution from recent equity issuance. The dividend yield appears sustainable given cash flow trends, supporting income investors amid steady utility growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
